Negligible Clinical Effects of Thalidomide in Patients with Myelofibrosis with Myeloid Metaplasia
- 1 January 2002
- journal article
- clinical trial
- Published by Springer Nature in Medical Oncology
- Vol. 19 (2), 79-86
- https://doi.org/10.1385/mo:19:2:79
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Thalidomide in agnogenic and secondary myelofibrosisBritish Journal of Haematology, 2001
- Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromesBlood, 2001
- Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasiaBritish Journal of Haematology, 2001
- Bone Marrow in Polycythemia Vera, Chronic Myelocytic Leukemia, and Myelofibrosis Has an Increased VascularityThe American Journal of Pathology, 2000
- Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myelomaBritish Journal of Haematology, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976-1995American Journal of Hematology, 1999
- Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of NeovascularizationExperimental Eye Research, 1997
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Life expectancy of patients with chronic nonleukemic myeloproliferative disordersCancer, 1991